Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) saw an upside of 4.71% to close Tuesday at $11.55 after adding $0.52 on the day. The 5-day average trading volume is 4,322,820 shares of the company’s common stock. It has gained $13.50 in the past week and touched a new high 1 time within the past 5 days. An average of 13,227,920 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 6,467,794.
RXRX’s 1-month performance is 60.19% or $4.69 on its low of $6.68 reached on 07/11/23. The company’s shares have touched a 52-week low of $4.54 and high of $16.75, with the stock’s rally to the 52-week high happening on 07/19/23. YTD, RXRX has achieved 49.81% or $3.84 and has reached a new high 14 times. However, the current price is down -31.02% from the 52-week high price.
Insider Transactions
RXRX stock investors last saw insider trading activity on Aug 02.Gibson Christopher (Chief Executive Officer) most recently sold 65,015 shares at $13.04 per share on Aug 02. This transaction cost the insider $847,712. President and COO, Larson Tina Marriott, sold 8,000 shares at a price of $13.62 on Jul 27. Then, on Jul 26, Chief Business Officer Virani Shafique sold 20,000 shares at a price of $14.41 per share. This transaction amounted to $288,200.
Valuation Metrics
RXRX stock has a beta of -0.11. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 47.58 while the price-to-book (PB) in the most recent quarter is 5.16.
Recursion Pharmaceuticals Inc.’s quick ratio for the period ended March 30 was 5.30, with the current ratio over the same period at 5.30.. In terms of profitability, the gross margin trailing 12 months is -13.50%. The trailing 12-month EBITDA margin is -567.83%. The firm’s gross profit as reported stood at -$8.43 million against revenue of $39.84 million.
Earnings Surprise
For the quarterly period ending March 30 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 14.56% to -$76.73 million, while revenue of -$65.33 million was 14.86% off the previous quarter. Analysts expected RXRX to announce -$0.35 per share in earnings in its latest quarter, but it posted -$0.34, representing a 2.90% surprise. EBITDA for the quarter stood at more than -$66.14 million. RXRX stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 197.19 million, with total debt at $53.05 million. Shareholders hold equity totaling $192.36 million.
Let’s look briefly at Recursion Pharmaceuticals Inc. (RXRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 August was 42.53% to suggest the stock is trending Neutral, with historical volatility in this time period at 87.30%.
The stock’s 5-day moving average is $12.10, reflecting a -16.40% or -$2.26 change from its current price. RXRX is currently trading +70.35% above its 20-day SMA, +54.41% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +33.37% and SMA200 by+15.27%.
Stochastic %K and %D was 10.78% and 13.09% and the average true range (ATR) pointed at 1.39. The RSI (14) points at 48.31%, while the 14-day stochastic is at 17.87% with the period’s ATR at 1.37. The stock’s 9-day MACD Oscillator is pointing at -1.06 and -1.72 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Recursion Pharmaceuticals Inc. (NASDAQ: RXRX), Morgan Stanley launched coverage with an Equal-weight rating. Analysts offering their rating for RXRX stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate RXRX as a “sell,”, while 5 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 3 have offered a “buy” rating.
What is RXRX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $9.00 and a high of $35.00, with their median price target at $12.50. Looking at these predictions, the average price target given by analysts is for Recursion Pharmaceuticals Inc. (RXRX) stock is $15.13.
